- Meeting abstract
- Open access
- Published:
Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated with Reduced NT-proANP, Increased Stroke and Higher Diastolic Blood Pressure
BMC Pharmacology and Toxicology volume 16, Article number: A37 (2015)
Introduction
The goal of this study was to identify genetic determinants of plasma N-terminal proatrial natriuretic peptide (NT-proANP) in the general community by performing a large-scale genetic association study and to assess its functional significance in in vitro cell studies and on disease susceptibility.
Methods and results
Genotyping was performed across 16,000 genes in 893 randomly selected individuals, with replication in 891 subjects from the community. Plasma NT-proANP1–98 concentrations were determined using a radioimmunoassay. Thirty-three genome-wide significant single-nucleotide polymorphisms were identified in the MTHFR-CLCN6-NPPANPPB locus and were all replicated. To assess the significance, in vitro functional genomic studies and clinical outcomes for carriers of a single-nucleotide polymorphism rs5063 (V32M) located in NPPA that represented the most significant variation in this genetic locus were assessed. The rs5063 variant allozyme in transfected HEK293 cells was decreased to 55±8% of wild-type protein (p=0.01) as assessed by quantitative western blots. Carriers of rs5063 had lower NT-proANP levels (1427 versus 2291 pmol/L; P<0.001) and higher diastolic blood pressures (75 versus 73 mm Hg; p=0.009) and were at an increased risk of stroke when compared with wild-type subjects independent of age, sex, diabetes mellitus, hypertension, atrial fibrillation, and cholesterol levels (hazard ratio, 1.6; p=0.004).
Conclusion
This is the first large-scale genetic association study of circulating NT-proANP levels performed with replication and functional assessment that identified genetic variants in the MTHFR-CLCN6-NPPA-NPPB cluster to be significantly associated with NT-proANP levels. The clinical significance of this variation is related to lower NT-proANP levels, higher blood pressures, and an increased risk of stroke in the general community.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access  This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made.
The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder.
To view a copy of this licence, visit https://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (https://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Pereira, N.L., Tosakulwong, N., Scott, C.G. et al. Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated with Reduced NT-proANP, Increased Stroke and Higher Diastolic Blood Pressure. BMC Pharmacol Toxicol 16 (Suppl 1), A37 (2015). https://doi.org/10.1186/2050-6511-16-S1-A37
Published:
DOI: https://doi.org/10.1186/2050-6511-16-S1-A37